Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report

Norwegian hepatitis C patients are waiting longer than they should for medical treatment due in part to a monopoly on its supply, according to a report. Between 15,000 and 20,000 Norwegians live with the chronic condition, which is treated with a 12-week course of medicine. The cost of a 12-week course of the Epclusa medicine in Norway is 540,000 kroner (57,000 euros), according to the Klassekampen newspaper. American pharmaceutical company Gilead S